Glenmark Specialty SA Secures FDA Nod for Asthma Inhaler

In a significant milestone for Glenmark Pharmaceuticals, its Swiss subsidiary Glenmark Specialty SA has obtained approval from the U.S. Food and Drug Administration (FDA) for Fluticasone Propionate Inhalation Aerosol USP. This product is the first generic equivalent of GlaxoSmithKline’s Flovent HFA, widely prescribed for asthma management.

The inhaled corticosteroid works by reducing lung inflammation, helping prevent symptoms such as wheezing and shortness of breath. With this approval, Glenmark enters the U.S. market with a cost-effective alternative, addressing the growing demand for affordable respiratory therapies. Analysts view this as a strategic win, reinforcing Glenmark’s position in the global generics space.

Key Highlights

• FDA Approval: First generic version of Flovent HFA cleared.
• Indication: Maintenance treatment of asthma in patients aged 4+.
• Mechanism: Reduces lung inflammation, prevents asthma symptoms.
• Market Impact: Expands access to affordable respiratory care in the U.S.
• Strategic Win: Strengthens Glenmark’s global respiratory portfolio.

Sources: U.S. Food and Drug Administration (FDA), CDSCO, ClinicalTrials.gov